株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオシミラーモノクロナール抗体 (MAb) の世界市場予測 2017-2027年:Infliximab / Rituximab / Trastuzumab / Trastuzumab/ Adalimumab / Bevacizumab / Abciximab のバイオシミラー

Global Biosimilar Monoclonal Antibodies Forecast 2017-2027: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

発行 Visiongain Ltd 商品コード 275993
出版日 ページ情報 英文 204 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=145.77円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
バイオシミラーモノクロナール抗体 (MAb) の世界市場予測 2017-2027年:Infliximab / Rituximab / Trastuzumab / Trastuzumab/ Adalimumab / Bevacizumab / Abciximab のバイオシミラー Global Biosimilar Monoclonal Antibodies Forecast 2017-2027: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab
出版日: 2017年05月19日 ページ情報: 英文 204 Pages
概要

世界のバイオシミラーモノクロナール抗体 (MAb) 市場は、2015年から2027年にかけて23.8%のCAGR (年間複合成長率) で拡大すると予測されています。同市場の規模は2020年に42億米ドル、2027年に79億米ドルが推計されています。

当レポートでは、世界のバイオシミラーモノクロナール抗体 (MAb) 市場について調査し、市場予測、2次市場別の収益予測、上市・開発中のバイオシミラー抗体別の収益予測、主要国市場の分析と予測、STEP分析および主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 レポート概要

第2章 イントロダクション:バイオシミラーモノクロナール抗体

  • 自然抗体:免疫システムの鍵
  • 血清療法からモノクロナール抗体 (MAbs) へ
  • MAbヒト化
  • 生物製剤とバイオシミラー
  • バイオシミラーの需要が高いのはなぜか?
  • バイオシミラー開発の検討事項
  • 既に上市されているバイオシミラーモノクロナール抗体

第3章 バイオシミラーモノクロナール抗体の世界市場予測

  • 現在の世界におけるバイオシミラーモノクロナール抗体市場
  • 世界のバイオシミラーMAb市場:収益予測
  • 世界のバイオシミラーMAb市場‐化合物別:収益・市場シェア予測
  • 世界のバイオシミラーMAb市場‐化合物別:収益予測
  • バイオシミラーMAb市場の成長促進因子・抑制因子
  • バイオシミラーMAb市場の成長抑制因子

第4章 各バイオシミラーMAb製品:上市薬・パイプライン薬

  • 上市されているバイオシミラーMAb
  • パイプラインバイオシミラー

第5章 主要国のバイオシミラーモノクロナール抗体市場

  • 主要国市場のバイオシミラーMAb状況は?
  • 主要国市場のシェアは予測期間を通してどう変化するか?
  • インド:バイオシミラーMAbで現在首位となっているが成長は減速する見通し
  • ロシア:規制の枠組みの欠如が短期的にはうまくいく
  • 韓国:市場は早期のバイオシミラーガイドラインから恩恵を受ける
  • 中国:細分化したバイオシミラーMAb市場
  • ブラジル:ANVISAのバイオシミラー規制はEMAと類似
  • EUにおけるバイオシミラーMAbの展望
  • 日本におけるバイオシミラーMAbの展望
  • 米国におけるバイオシミラーMAbの展望

第6章 主要企業

  • バイオシミラーMAb開発におけるコラボレーション
  • BioXpress:特許満了日をターゲットに
  • Celltrion:企業の市場規模は107億米ドル以上に急増
  • Harvest Moon:6つの化合物が開発中
  • Genor Biopharma:中国におけるバイオシミラーMAbの市場リーダー
  • Samsung Bioepsis
  • Mabion:ポーランドの主要バイオシミラーMAb開発企業
  • Gene Techno Science:持続的な収益拡大
  • インドのBiocon
  • Coherus Biosciences
  • BIOCAD:バイオシミラー Rituximab 売上の世界のリーダー
  • 大手企業とバイオシミラーMAb市場
  • バイオシミラーMAb市場における注目の買収

第7章 バイオシミラーモノクロナール抗体市場の定性的分析

  • 強みと弱み
  • 機会と脅威
  • バイオシミラーMAb市場に影響を及ぼす社会、技術、経済および政治的要因 (STEP分析)

第8章 結論

  • バイオシミラーモノクロナール抗体:世界市場
  • 市場・パイプラインにおける化合物の将来
  • 主要国市場
  • 主要企業
  • 産業動向の現状・予測

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0194

The global biosimilar monoclonal antibodies market is expected to grow at a CAGR of 9.6% in the second half of the forecast period. The market is expected to grow at a CAGR of 23.8% from 2015-2027. The market is estimated at $4.2bn in 2020 and $7.9bn in 2027.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 204-page report you will receive 72 tables and 72 figures - all unavailable elsewhere.

The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Biosimilar Monoclonal Antibodies Market forecasts from 2017-2027
  • Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2027 for the market segmented by compound:
    • Infliximab
    • Rituximab
    • Abciximab
    • Trastuzumab
    • Adalimumab
    • Bevacizumab
  • This report also shows revenue to 2027 for individual biosimilar mAb products in the market:
    • Remsima/Inflectra
    • Infimab
    • Reditux
    • BI695500
    • CT-P10
    • BI695501
    • FKB327
    • FKB238
    • Mabtas
    • AcellBia
    • Maball
    • Clotinab
    • Abcixirel
    • BCD-022
    • BCD-021
    • Herzuma
    • CANMAB/Hertraz
  • Our analyses show individual revenue forecasts to 2027 for these regional and national markets:
    • The US Biosimilar mAb Market
    • Japanese Biosimilar mAb Market
    • EU5 Biosimilar mAb Markets
    • BRIC and South Korea Biosimilar mAb Markets
    • Rest of the World Biosimilar mAb Market
  • This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline
  • Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market

Visiongain's study is intended for anyone requiring commercial analyses for the biosimilars monoclonal antibodies market. You find data, trends and predictions.

Buy our report today Global Biosimilar Monoclonal Antibodies Forecast 2017-2027: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of Biosimilar Monoclonal Antibodies: R&D, Industry and Market
  • 1.2. Why You Should Read this Report
  • 1.3. How This Study Delivers
  • 1.4. Main Questions Answered by the Analysis
  • 1.5. Who is This Investigation For?
  • 1.6. Method of Research and Analysis
  • 1.7. Frequently Asked Questions (FAQs)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Introduction to Biosimilar Monoclonal Antibodies

  • 2.1. Natural Antibodies: Key to the Immune System
  • 2.2. From Serum therapy to Monoclonal Antibodies
  • 2.3. Humanising the mAb
  • 2.4. Biologics (Biological Drugs) and Biosimilars
  • 2.5. Why are Biosimilars in High Demand?
  • 2.6. Considerations for the Development of Biosimilars
    • 2.6.1. Biologics and Biosimilars Are Large, Complex Molecules
    • 2.6.2. How Much of a Concern is Immunogenicity?
  • 2.7. Biosimilar Monoclonal Antibodies Currently on the Market

3. The Global Market for Biosimilar Monoclonal Antibodies, 2016-2027

  • 3.1. The Present Global Market for Biosimilar Monoclonal Antibodies
  • 3.2. The Global Market for Biosimilar mAbs: A Revenue Forecast, 2016-2027
  • 3.3. The Global Market for Biosimilar mAbs by Compound: Predictions for Revenue and Market Share in 2020 and 2027
  • 3.4. The World Market for Biosimilar mAbs by Compound: Revenue Forecasts, 2016-2027
    • 3.4.1. Will Biosimilar Versions of Monoclonal Antibodies Capture a Large Proportion of the Market?
    • 3.4.2. Biosimilar Infliximab: Currently the Second Largest Submarket
      • 3.4.2.1. Biosimilar Infliximab Revenue Forecast 2016-2027
    • 3.4.3. Biosimilar Rituximab: The Current Leading Submarket Driven by Sales in Russia
      • 3.4.3.1. Biosimilar Rituximab: Revenue Forecast 2016-2027
    • 3.4.4. Biosimilar Abciximab: Revenue Forecast 2016-2027
      • 3.4.4.1. Biosimilar Abciximab: Revenue Forecast, 2016-2027
    • 3.4.5. Biosimilar Trastuzumab: Pipeline Rich in Phase III Candidates
      • 3.4.5.1. Biosimilar Trastuzumab: Revenue Forecast, 2016-2027
    • 3.4.6. Biosimilar Adalimumab: Patents Hold Back Revenue on a Large Pipeline
      • 3.4.6.1. Biosimilar Adalimumab: Revenue Forecast 2016-2027
    • 3.4.7. Biosimilar Bevacizumab: Will Late Entry to the Biosimilar mAb Market Restrict Revenue?
      • 3.4.7.1. Biosimilar Bevacizumab: Revenue Forecast, 2016-2027
  • 3.5. Drivers and Restraints for the Biosimilar mAb market 2016-2027
    • 3.5.1. Driving Factors of the Biosimilar mAb Market 2016-2027
  • 3.6. Restraining Factors of the Biosimilar mAb Market 2016-2027

4. Individual Biosimilar mAb Products: Marketed and Pipeline Drugs, 2016-2027

  • 4.1. Biosimilar mAbs on the Market in 2017
    • 4.1.1. Celltrion's Remsima/ Hospira's Inflectra. Egis' Flammegis (Infliximab): The First Official Biosimilar Monoclonal Antibody
      • 4.1.1.1. Remsima/Inflectra/Flammegis Revenue Forecast, 2016-2027
    • 4.1.2. Infimab (Infliximab): Launched a Quarter Ahead of Schedule
      • 4.1.2.1. Infimab Revenue Forecast ($m) 2016-2027
    • 4.1.3. Dr Reddy's Reditux (Rituximab): No Application for EU or US Approval
      • 4.1.3.1. Reditux Revenue Forecast, 2016-2027
    • 4.1.4. Intas Pharmaceuticals' Mabtas (Rituximab)
      • 4.1.4.1. Mabtas (Rituximab) Revenue Forecast 2016-2027
    • 4.1.5. AcellBia (Rituximab): Sales in Russia Generating Large Revenue Figures
      • 4.1.5.1. AcellBia Revenue Forecast 2016-2027
    • 4.1.6. MABALL: Faces Competition from other Biosimilar Rituximabs in India
      • 4.1.6.1. MABALL Revenue Forecast, 2016-2027
    • 4.1.7. Isu Abxis' Clotinab (abciximab):
      • 4.1.7.1. Clotinab Revenue Forecast, 2016-2027
    • 4.1.8. AbcixiRel: The First Indian Abciximab Biosimilar
      • 4.1.8.1. AbcixiRel Revenue Forecast 2016-2027
    • 4.1.9. Herzuma (Trastuzumab): Approved in South Korea
      • 4.1.9.1. Herzuma Revenue Forecast 2016-2027
    • 4.1.10. CANMAb/Hertraz (Trastuzumab)
      • 4.1.10.1. CANMAb/Hertraz Revenue Forecast, 2016-2027
  • 4.2. Pipeline Biosimilars
    • 4.2.1. BI695500 (Rituximab): An EU Launch Anticipated in 2017
      • 4.2.1.1. BI695500 Revenue Forecast, 2016-2027
    • 4.2.2. CT-P10 (Rituximab): Celltrion's Reputation for Biosimilars will Assist Sales
      • 4.2.2.1. Celltrion's CT-P10 (Rituximab) Revenue Forecast, 2016-2027
    • 4.2.3. Boehringer Ingelheim's BI695501 (Adalimumab)
      • 4.2.3.1. BI695501 Revenue Forecast, 2016-2027
    • 4.2.4. BCD-022 (Trastuzumab): Currently under Development in Russia Only
      • 4.2.4.1. BCD-022 Revenue Forecast, 2016-2027
    • 4.2.5. Fujifilm Kyowa Kirin Biologics' FKB327 (Adalimumab)
      • 4.2.5.1. FKB327 Revenue Forecast, 2016-2027
    • 4.2.6. Fujifilm Kyowa Kirin Biologics' FKB238 (Bevacizumab)
      • 4.2.6.1. Fujifilm Kyowa Kirin Biologics' FKB238 Revenue Forecast 2016-2027
    • 4.2.7. BCD-021 (Bevacizumab): Russia Will Contribute the Most Revenue
      • 4.2.7.1. BCD-021 Revenue Forecast 2016-2027

5. Leading National Markets for Biosimilar Monoclonal Antibodies

  • 5.1. What Were the Leading National Markets for Biosimilar mAbs in 2016?
  • 5.2. How Will National Market Shares Change Over the Forecast Period?
  • 5.3. India: The Current Leading Nation for Biosimilar mAbs but Growth will Slow
    • 5.3.1. India Releases New Biosimilar Development Guidelines
    • 5.3.2. Indian Biosimilar Submarket Forecast 2016-2027
  • 5.4. Russia: Lack of Regulatory Framework Works Well in the Short Term
    • 5.4.1. Russian Government Backed ‘Pharma 2020' Initiative
    • 5.4.2. Russian Biosimilar mAb Revenue Forecast, 2016-2027
  • 5.4. South Korean Market has Benefitted from Early Biosimilar Guidelines
    • 5.4.1. Significant Investment in Biosimilars in South Korea
    • 5.4.2. South Korean Biosimilar mAb Revenue Forecast, 2016-2027
  • 5.5. China: A Fragmented Biosimilar mAb Market
    • 5.5.1. Chinese FDA Publishes Finalised Biosimilar Guidelines in 2015
    • 5.5.2. China Biosimilar mAb Revenue Forecast, 2016-2027
  • 5.6. Brazil: ANVISA's Biosimilar Regulations Are Similar the EMA's
    • 5.6.1. Brazil Biosimilar mAb Revenue Forecast 2016-2027
  • 5.7. The Outlook for Biosimilar mAbs in the EU 2016-2027
    • 5.7.1. Updating Biosimilar Regulation: Guidelines for the Specific Approval of Biosimilar mAbs
    • 5.7.2. Biosimilar mAbs in the EU5: Revenue Forecasts, 2016-2027
    • 5.7.3. Germany: The Current EU Leader
    • 5.7.4. France: Will the Uptake of Biosimilar mAbs be Restricted?
    • 5.7.5. UK: NICE Recommends Use of Remsima for Certain Indications
    • 5.7.6. Italy: Healthcare Spending Cuts Will Drive Growth
    • 5.7.7. Spain: High Biosimilar mAb Discounts Expected
  • 5.8. The Outlook for Biosimilar mAbs in Japan
    • 5.8.1. Regulations for Naming Biosimilars
    • 5.8.2. Biosimilar mAb Market Activity in Japan
    • 5.8.3. Japanese Biosimilar Submarket Forecast 2016-2027
  • 5.9. US Biosimilar mAb Outlook: None Currently on the Market
    • 5.9.1. US FDA Biosimilar Guidelines were Released in 2015
    • 5.9.2. Legal Challenges for Biosimilars in the US
    • 5.9.3. State Regulation of Biosimilar Substitution
    • 5.9.4. The US Biosimilar mAb Market Revenue Forecast, 2015-2027

6. Leading Companies in the Biosimilar Monoclonal Antibodies Market

  • 6.1. Collaboration in Biosimilar mAb Development
  • 6.2. BioXpress: Targeting Patent Expiry Dates in 2019-2023
  • 6.3. Celltrion: Company's Market Value Surges to Exceed $10.7bn
  • 6.4. Harvest Moon: Six Compounds Under Development
  • 6.5. Genor Biopharma: A Biosimilar mAb Market Leader in China
  • 6.6. Samsung Bioepsis
  • 6.7. Mabion: Poland's Leading Biosimilar mAb Developer
  • 6.8. Gene Techno Science: Substantial Revenue Increases Since 2014
  • 6.9. India's Biocon:
  • 6.10. Coherus Biosciences
  • 6.11. BIOCAD: World Leader Biosimilar Rituximab Sales
  • 6.12. Big Pharma and the Biosimilar mAb Market
  • 6.13. Significant Acquisitions in the Biosimilar mAb Market
    • 6.13.1. Pfizer Acquires Hospira
    • 6.13.2. Epirus Acquires Bioceros

7. Qualitative Analysis of Biosimilar Monoclonal Antibodies Market

  • 7.1. Strengths and Weaknesses of the Biosimilar Monoclonal Antibodies Market, 2016-2027
    • 7.1.1. Global Demand for Affordable Biopharmaceuticals has Never Been Greater
    • 7.1.2. Adoption of Biosimilar mAbs will be Proportional to the Rate of Discount
    • 7.1.3. Approval Pathways are Now Established in Developed Markets
    • 7.1.4. Complexity of Protein Molecules Leads to Technical Challenges
    • 7.1.5. Doctor and Patient Confidence May Take Time
  • 7.2. Opportunities and Threat Facing the Biosimilar Monoclonal Antibodies Market, 2016-2027
    • 7.2.1. Market Opportunities from Patent Expiries and a Well-stocked Pipeline
    • 7.2.2. Substitution may Not Occur Automatically
    • 7.2.3. Biobetters Offer a Serious Threat to the Production and Uptake of Biosimilars
  • 7.3. Social and Technological Forces Influencing the Biosimilar Monoclonal Antibodies Market 2016-2027
    • 7.3.1. Social Factors: Driving or Restraining the Market?
    • 7.3.2. Technological Factors Concentrate on Reducing Costs and Increasing Ease of Production
    • 7.3.3. Economic Pressures Raise Demand for Biosimilar mAbs
      • 7.3.3.1. Fragmentation of the Market Could Limit Individual Drug Revenues
    • 7.3.4. Political Issues: Stringent Regulations Hurdles to Market Entry

8. Conclusions

  • 8.1. Biosimilar Monoclonal Antibodies: World Market, 2016-2027
  • 8.2. Future of Compounds on the Market and in the Pipeline
  • 8.3. Leading National Markets for Biosimilar Monoclonal Antibodies 2016-2027
  • 8.4. Leading Companies in the Biosimilar mAb Market
  • 8.5. Current and Expected Industry Trends 2016-2027
    • 8.5.1. Cost Control of Healthcare Will Work in Favour mAbs
    • 8.5.2. Upcoming Patent Expiries in Developed Markets Offer Large Market Potential
    • 8.5.3. Complex Production Processes are a Restraining Factor
    • 8.5.4. Clinician and Patient Confidence Must be Maximised to Ensure Uptake
    • 8.5.5. Biobetters Pose a Threat
  • Visiongain Report Sales Order Form
  • Associated Visiongain Reports
  • About Visiongain
  • Visiongain report evaluation form

List of Figures

  • Figure 1.1: Main Compound Classes of Biosimilar mAbs, 2017
  • Figure 2.1: Structure of an Antibody
  • Figure 3.1: Global Market for Biosimilar mAbs: Revenue forecast ($m), 2016-2027
  • Figure 3.2: The Biosimilar mAb Market: Market Share (%) by compound in 2017
  • Figure 3.3: The Biosimilar mAb Market: Market Share (%) by compound in 2020
  • Figure 3.4: The Biosimilar mAb Market: Market Share (%) by compound in 2027
  • Figure 3.5: Biosimilar Infliximab: Global Revenue ($m) Forecast 2016-2027
  • Figure 3.6: Biosimilar Rituximab: Global Revenue ($m) Forecast 2016-2027
  • Figure 3.7: Biosimilar Abciximab: Global Revenue ($m) Forecast 2016-2027
  • Figure 3.8: Biosimilar Trastuzumab: Global Revenue ($m) Forecast 2016-2027
  • Figure 3.9: Biosimilar Adalimumab: Global Revenue ($m) Forecast 2016-2027
  • Figure 3.10: Biosimilar Bevacizumab: Global Revenue ($m) Forecast 2016-2027
  • Figure 3.11: Drivers and Restraints for the Global Biosimilar mAb market 2016-2027
  • Figure 4.1: Biosimilar mAb Versions on the Market: Market Share (%) 2017
  • Figure 4.2: Biosimilar mAb Versions on the Market: Market Share (%) 2020
  • Figure 4.3: Biosimilar mAb Versions on the Market: Market Share (%) 2027
  • Figure 4.4: Remsima/Inflectra/Flammegis (Infliximab): Revenue Forecast ($m), 2016-2027
  • Figure 4.5: Remsima/Inflectra/Flammegis (Infliximab): AGR Forecast (%), 2016-2027
  • Figure 4.6: Infimab (Infliximab): Revenue Forecast ($m) 2016-2027
  • Figure 4.7: Infimab (Infliximab): AGR Forecast (%) 2016-2027
  • Figure 4.8: Reditux (Rituximab): Revenue Forecast ($m) 2016-2027
  • Figure 4.9: Reditux (Rituximab): AGR Forecast (%) 2016-2027
  • Figure 4.10: Mabtas (Rituximab): Revenue Forecast ($m) 2016-2027
  • Figure 4.11: Mabtas (Rituximab): AGR Forecast (%) 2016-2027
  • Figure 4.12: AcellBia (Rituximab): Revenue Forecast ($m) 2016-2027
  • Figure 4.13: AcellBia (Rituximab): AGR Forecast(%) 2016-2027
  • Figure 4.14: MABALL (Rituximab): Revenue Forecast ($m) 2016-2027
  • Figure 4.15: MABALL (Rituximab): AGR Forecast(%) 2016-2027
  • Figure 4.16: Clotinab (Abciximab): Revenue Forecast ($m) 2016-2027
  • Figure 4.17: Clotinab (Abciximab): AGR Forecast (%) 2016-2027
  • Figure 4.18: AbcixiRel (Abciximab): Revenue Forecast ($m) 2016-2027
  • Figure 4.19: AbcixiRel (Abciximab): AGR Forecast (%) 2016-2027
  • Figure 4.20: Herzuma (Trastuzumab): Revenue Forecast ($m) 2016-2027
  • Figure 4.21: Herzuma (Trastuzumab): AGR Forecast (%) 2016-2027
  • Figure 4.22: CANMAb/Hertraz (Trastuzumab): Revenue Forecast ($m) 2016-2027
  • Figure 4.23: CANMAb/Hertraz (Trastuzumab): AGR Forecast (%) 2016-2027
  • Figure 4.24: BI695500 (Rituximab): Revenue Forecast ($m) 2017-2027
  • Figure 4.25: BI695500 (Rituximab): AGR Forecast (%) 2018-2027
  • Figure 4.26: CT-P10 (Rituximab): Revenue Forecast ($m) 2018-2027
  • Figure 4.27: CT-P10 (Rituximab): AGR Forecast (%) 2019-2027
  • Figure 4.28: BI695501 (Adalimumab): Revenue Forecast ($m) 2017-2027
  • Figure 4.29: BI695501 (Adalimumab): AGR Forecast (%)2018-2027
  • Figure 4.30: BCD-022 (Trastuzumab): Revenue Forecast ($m) 2016-2027
  • Figure 4.31: BCD-022 (Trastuzumab): AGR Forecast (%) 2017-2027
  • Figure 4.32: FKB327 (Adalimumab): Revenue Forecast ($m) 2017-2027
  • Figure 4.33: FKB327 (Adalimumab): AGR Forecast (%) 2018-2027
  • Figure 4.34: FKB238 (Adalimumab): Revenue Forecast ($m) 2020-2027
  • Figure 4.35: FKB238 (Adalimumab): AGR Forecast(%) 2021-2027
  • Figure 4.36: BCD-021 (Bevacizumab): Revenue Forecast ($m) 2017-2027
  • Figure 4.37: BCD-021 (Bevacizumab): AGR Forecast (%) 2018-2027
  • Figure 5.1: The Biosimilar MAb Market by Country: Market Shares (%) of Revenue, 2016
  • Figure 5.2: The Biosimilar MAb Market: National Submarket Shares (%), 2020
  • Figure 5.3: The Biosimilar MAb Market: National Submarket Shares (%), 2027
  • Figure 5.4: The Indian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.5: The Russian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.6: The South Korean Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.7: The Chinese Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.8: The Brazilian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.9: The EU5 Biosimilar mAb Market: Grouped Revenue Forecast ($m), 2016-2027
  • Figure 5.10: The EU5 Biosimilar mAb Market: Revenue Forecasts ($m) by Country, 2016-2027
  • Figure 5.11: The German Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.12: The French Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.13: The UK Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.14: The Italian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.15: The Spanish Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.16: The Japanese Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Figure 5.17: Biosimilar mAbs in the US: Revenue Forecast ($m), 2017-2027
  • Figure 6.1: Prominent Companies in the Biosimilar mAb Industry: Share (%) of the Pipeline,
  • Figure 8.1: Prominent Compounds in the Biosimilar mAb Market: Comparison of Revenues ($m), 2017, 2020 and 2027
  • Figure 8.2: Forecasted Biosimilar mAbs: Comparison of Revenues ($m), 2017, 2020 and 2027
  • Figure 8.3: Leading National Markets: Revenues ($m), 2017, 2020 and 2027
  • Figure 8.4: Prominent Companies in the Biosimilar mAb Industry: Number of Products in Current Development or in the Pipeline, 2017

List of Tables

  • Table 1.1: Biosimilar mAbs: Global Revenue Forecast by Reference Compound 2016-2027
  • Table 2.1: Classification of Monoclonal Antibodies
  • Table 2.2: Murine Monoclonal Antibodies on the Market, 2017
  • Table 2.3: Chimeric Monoclonal Antibodies on the Market, 2017
  • Table 2.4: Humanised Monoclonal Antibodies on the Market, 2017
  • Table 2.5: Fully Human Monoclonal Antibodies on the Market, 2017
  • Table 2.6: Revenue of Originator Monoclonal Antibody Products in 2016
  • Table 3.1: Biosimilar mAb Global Market: Revenue Forecast ($m), 2016-2027
  • Table 3.2: Global Market for Biosimilar mAbs: Revenues ($m) and Market Shares (%) by Reference Compound, 2017, 2020 and 2027
  • Table 3.3: EU and US Patent Expiry Dates for the Main mAb Reference Products
  • Table 3.4: Biosimilar mAbs: Global Revenue Forecast by Reference Compound 2016-2027
  • Table 3.5: Biosimilar Infliximab: Compounds Awaiting Approval in the Pipeline
  • Table 3.6: Biosimilar Infliximab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2027
  • Table 3.7: Biosimilar Rituximab: Compounds Marketed and in the Pipeline, 2017
  • Table 3.8: Biosimilar Rituximab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2027
  • Table 3.9: Biosimilar Abciximab: Compounds Marketed and in the Pipeline, 2016
  • Table 3.10: Biosimilar Abciximab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2027
  • Table 3.11: Biosimilar Trastuzumab: Compounds Marketed and in the Pipeline, 2017
  • Table 3.12: Biosimilar Trastuzumab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2027
  • Table 3.13: Biosimilar Adalimumab: Compounds Marketed and in the Pipeline, 2017
  • Table 3.14: Biosimilar Adalimumab: Global Revenue Forecast 2016-2027
  • Table 3.15: Biosimilar Bevacizumab: Compounds Marketed and in the Pipeline, 2017
  • Table 3.16: Biosimilar Bevacizumab: Global Revenue Forecast ($m), AGR (%) and CAGR (%) 2016-2027
  • Table 4.1: Biosimilar mAbs on the Market in 2017: Revenues ($m) and Market Shares (%)
  • Table 4.2: Remsima/Inflectra/Flammegis (Infliximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.3: Infimab (Infliximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.4: Reditux (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.5: Mabtas (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.6: Biocad Distribution Partners for AcellBia, 2016
  • Table 4.7: AcellBia (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.8: MABALL (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.9: Clotinab (Abciximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.10: AbcixiRel (Abciximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.11: Herzuma (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.12: CANMAb/Hertraz (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.13: BI695500 (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 4.14: CT-P10 (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2018-2027
  • Table 4.15: BI695501 (Adalimumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 4.16: BCD-022 (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.17: FKB327 (Adalimumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 4.18: FKB238 (Bevacizumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2020-2027
  • Table 4.19: BCD-021 (Bevacizumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2027
  • Table 5.1: Leading National Markets for the Global Biosimilar mAb Industry, 2016
  • Table 5.2: Leading National Markets for the Global Biosimilar mAb Industry, 2016-2027
  • Table 5.3: The Indian Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.4: The Russian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.5: The South Korean Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.6: The Chinese Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.7: The Brazilian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.8: The EU5 Biosimilar mAb Market: Revenue Forecast ($m), 2016-2027
  • Table 5.9: The German Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.10: The French Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.11: The UK Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.12: The Italian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.13: The Spanish Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.14: The Japanese Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2027
  • Table 5.15: Finalised FDA Biosimilar Guidelines, 2015
  • Table 5.16: The US Biosimilar mAb Market: Revenue ($m) and Annual Growth (%) Forecast, 2017-2027
  • Table 6.1: Companies in the Biosimilar mAb Industry by Number of Compounds in Development, 2017
  • Table 6.2: Selected Collaborations for Biosimilar mAb Development, 2009-2017
  • Table 6.3: BioXpress: Compounds in the Pipeline, 2017
  • Table 6.4: Tests Carried Out By BioXpress During Biosimilar mAb Development, with Objectives
  • Table 6.5: Compounds in Celltrion's Pipeline: Compound Name, Generic Name, Development Stage and Anticipated Year of Approval, 2017
  • Table 6.6: Genor Biopharma: Biosimilar mAbs Pipeline, 2017
  • Table 6.7: Mabion: Compounds in the Pipeline and Their Development Stage, 2017
  • Table 6.8: Gene Techno Science: Revenue ($m), from 2013-2017
  • Table 6.9: Biocon: Compounds in the Pipeline and Their Stage of Development, 2017
  • Table 6.10: Big Pharma's Positions in the Biosimilar mAb Industry, 2017
  • Table 6.11: Significant Acquisitions in the Biosimialr mAb Market 2017
  • Table 7.1: Strengths and Weaknesses of the Biosimilar mAb Market, 2016-2027
  • Table 7.2: Opportunities and Threats Facing the Biosimilar mAb Market, 2016-2027
  • Table 7.3: Social and Technological Factors Influencing the Biosimilar mAb Market, 2016-2027

Companies Listed

  • Abbott Laboratories
  • AbbVie
  • Aché
  • Actavis
  • AET BioTech
  • Alexion Pharmaceuticals
  • Alvogen
  • Alvotech
  • Amgen
  • Aprogen
  • Array Bridge
  • AstraZeneca
  • Bayer
  • Binex
  • BIO
  • BIOCAD
  • Biocerus
  • Biocon
  • Biogen Idec
  • Bio-Manguinhos
  • Bionovis
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cell Therapeutics
  • Celltrion
  • Celon Pharma Lomianki
  • CinnaGen
  • Coherus BioSciences
  • Daiichi Sankyo
  • Dong-A
  • Dr. Reddy's Laboratories
  • Egis Pharmaceuticals
  • Eli Lilly
  • Emcure
  • EMS
  • Epirus Biopharmaceuticals
  • Farmasa
  • Fresenius
  • Fujifilm Kyowa Kirin Biologics
  • Gedeon Richter
  • Gene Techno Science
  • Genentech
  • Genexo
  • Genor Biopharma
  • GlaxoSmithKline (GSK)
  • Glycotope
  • Hanwha Chemical
  • Harvest Moon
  • Hospira
  • Hypermarcas
  • iBio
  • IBSS Biomed
  • ImClone LLC
  • Instas Pharmaceuticals
  • Instituto Vital Brazil
  • IPCA Labs
  • Isu Abxis
  • Janssen
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Laboratorios Liomont
  • LG Life Sciences
  • Lonza
  • Mabion
  • mAbxience
  • MedImmune
  • Merck & Co.
  • Merck Serono
  • Millhouse LLC
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Mustafa Nevzat Pharmaceuticals
  • Mylan
  • Natco Pharma
  • Nichi-Iko Pharmaceutical Co.
  • Nippon Kayaku
  • Novartis
  • Oncobiologics
  • Otsuka Pharmaceutical
  • Parexel
  • Pfizer
  • PharmaPraxis
  • Pharmstandard
  • PhRMA
  • PlantForm
  • Polfarmex
  • Probiomed
  • QuantiaMD
  • Quintiles
  • Reliance Life Sciences
  • Roche
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • Schnell
  • Seattle Genetics
  • Shanghai CP Guojian
  • Shionogi
  • Sorrento
  • Spectrum Pharmaceuticals
  • Stada
  • Synthon
  • Takeda
  • Teva Pharmaceutical Industries
  • UCB
  • União Química
  • Viropro
  • Walvax Biotechnology
  • Wyeth
  • Zenotech
  • Zhejiang Huahai Pharmaceutical

Organizations Mentioned in the Report

  • Agence française de sécurité sanitaire des produits de santé (ANSM)
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Chinese Centre for Drug Evaluation (CDE)
  • Cour des Comptes (France)
  • European Medicines Agency (EMA)
  • Food and Drug Administration (US FDA)
  • Fraunhofer Center for Molecular Biology
  • Health Canada
  • India Brand Equity Foundation
  • Korean Food and Drug Administration (KFDA)
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Ministry of Food and Drug Safety (South Korea)
  • Ministry of Health (Russia)
  • Ministry of Health, Labour and Welfare (MHLW)
  • National Institute for Health and Care Excellence (NICE)
  • National Institute for Health Research Horizon Scanning Centre
  • Norwegian Medical Agency
  • Russian Ministry of Health
  • Scientific Centre for Expertise of Medicinal Application Products (Russia)
  • Spanish Ministry of Health
  • State Food and Drug Administration (SFDA)
  • The Cancer Centre Bahamas
  • Washington Legal Foundation
  • World Health Organization (WHO)
Back to Top